stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) Shares outstanding
Kodiak Sciences Inc.'s shares outstanding at the end of fiscal 2025 was $53.2M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $62.6M. Over the past ten years it has ranged from $7.2M (fiscal 2016) to $53.2M (fiscal 2025) — the current reading is the highest in ten years. Kodiak Sciences Inc. ranks 246th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $53.2M | 1.19% |
| FY2024 | $52.6M | 0.32% |
| FY2023 | $52.4M | 0.31% |
| FY2022 | $52.3M | 0.89% |
| FY2021 | $51.8M | 13.22% |
| FY2020 | $45.7M | 20.84% |
| FY2019 | $37.9M | 152.75% |
| FY2018 | $15.0M | 99.29% |
| FY2017 | $7.5M | 4.22% |
| FY2016 | $7.2M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $62.6M | 1.24% |
| Mar 2026 | $61.9M | 16.26% |
| Dec 2025 | $53.2M | 0.66% |
| Sep 2025 | $52.9M | 0.15% |
| 31 more quarters | Free account |
Against its own ten years
Low $7.2M
High $53.2M
Ten-year median
$48.8M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| KOD Kodiak Sciences Inc. | $62.6M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item